Sumitomo Mitsui, Amova Report 7.2% Stake in Arcturus Therapeutics

Sumitomo Mitsui Trust Group, Inc. and Amova Asset Management Co., Ltd. have filed a Schedule 13G/A amendment reporting their beneficial ownership of 7.2% of the common stock of Arcturus Therapeutics Holdings Inc. The filing indicates that both entities, classified as parent holding companies, non-U.S. institutions, and investment advisers, share voting and dispositive power over 1,947,835 shares. The securities are owned or deemed to be beneficially owned by their subsidiary, Amova Asset Management Americas, Inc. The filing certifies that the shares were acquired and are held in the ordinary course of business and not for the purpose of influencing the control of the issuer.